Myofibroblasts in pulmonary and brain metastases of alveolar soft-part sarcoma: A novel target for treatment?

Neoplasia

Volumn 10, Issue 9, 2008, Pages 940-948

  Genin, Olga ^a   Rechavi, Gideon ^b   Nagler, Arnon ^b   Ben Itzhak, Ofer ^c   Nazemi, Kellie J ^d   Pines, Mark ^a  

^a VOLCANI CENTER   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOGLOBIN; SCLEROPROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ALVEOLAR SOFT PART SARCOMA; ANIMAL EXPERIMENT; ARTICLE; BRAIN METASTASIS; CONTROLLED STUDY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; INCIDENCE; LUNG METASTASIS; MALE; MOUSE; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS;

EID: 50949115026     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.08456     Document Type: Article

References (52)

1. Folpe AL and Deyrup AT (2006). Alveolar soft-part sarcoma: a review and update. J Clin Pathol 59, 1127-1132.
2. Kayton ML, Meyers P, Wexler LH, Gerald WL, and LaQuaglia MP (2006). Clinical presentation, treatment, and outcome of alveolar soft part sarcoma in children, adolescents, and young adults. J Pediatr Surg 41, 187-193.
3. Ladanyi M, Lui MY, Antonescu CR, Krause-Boehm A, Meindl A, Argani P, Healey JH, Ueda T, Yoshikawa H, Meloni-Ehrig A, et al. (2001). The der (17)t(X;17)(pl l;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25. Oncogene 20, 48-57.
4. Azizi AA, Haberler C, Gupper A, Prayer D, Breitschopf H, Acker T and Slavc I (2006). Vascular-endothelial-growth-factor (VEGF) expression and possible response to angiogenesis inhibitor bevacizumab in metastatic alveolar soft part sarcoma. Lancet Oncol 7, 521-523.
5. Benetos IS, Mavrogenis AF, Soultanis KCh, Zoubos AB, Papagelopoulos PJ, and Soucacos PN (2006). Alveolar soft part sarcoma of the forearm: a case report. J Surg Orthop Adv 15, 209-213.
6. Liberman PH, Brennan F, Kimmel M, Erlandson RA, Garin-Chesa P, and Flehinger BY (1989). Alveolar soft-part sarcoma. A clinico-pathologic study of half a century. Cancer 63, 1-13.
7. Ogose A, Yazawa Y, Ueda T, Hotta T, Kawashima H, Hatano H, and Morita T (2003). Alveolar soft part sarcoma in Japan: multi-institutional study of 57 patients from the Japanese Musculoskeletal Oncology Group. Oncology 65, 7-13.
8. Portera CA Jr, Ho V, Patel SR, Hunt KK, Feig BW, Respondek PM, Yasko AW, Benjamin RS, Pollock RE, and Pisters PW (2001). Alveolar soft part sarcoma: clinical course and patterns of metastasis in 70 patients treated at a single institution. Cancer 91, 585-591.
9. van Kempen LC, Ruiter DJ, van Muijen GN, and Coussens LM (2003). The tumor microenvironment: a critical determinant of neoplastic evolution. Eur J Cell Biol 82, 539-548.
10. Shekhar MPV, Pauley R, and Heppner G (2003). Host microenvironment in breast cancer development: extracellular matrix - stromal cell contribution to neoplastic phenotype of epithelial cells in the breast. Breast Cancer Res 5, 130-135.
11. Lewis MP, Lygoe KA, Nystrom ML, Anderson WP, Speight PM, Marshall JF, and Thomas GJ (2004). Tumor-derived TGF-beta1 modulates myofibroblast differentiation and promotes HGF/SF-dependent invasion of squamous carcinoma cells. Br J Cancer 90, 822-832.
12. Micke P and Ostman A (2004). Tumour-stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy? Lung Cancer 45, S163-S175.
13. Chai J, Norng M, Tarnawski AS, and Chow J (2007). A critical role of serum response factor in myofibroblast differentiation during experimental oesophageal ulcer healing in rat. Gut 56, 621-630.
14. Verrecchia F and Mauviel A (2002). Transforming growth factor-beta signaling through the Smad pathway: role in extracellular matrix gene expression and regulation. J Invest Dermatol 118, 211-215.
15. Verrecchia F, Chu ML, and Mauviel A (2001). Identification of novel TGF-betal Smad gene targets in dermal fibroblasts using a combined cDNA microarray/ promoter transactivation approach. J Biol Chem 276, 17058-17062.
16. Untergasser G, Gander R, Lilg C, Lepperdinger G, Plas E, and Berger P (2005). Profiling molecular targets of TGF-betal in prostate fibroblast-to-myofibroblast transdifferentiation. Mech Ageing Dev 126, 59-69.
17. Qiu P, Feng XH, and Li L (2003). Interaction of Smad3 and SRF-associated complex mediates TGF-betal signals to regulate SM22 transcription during myofibroblast differentiation. J Mol Cell Cardiol 35, 1407-1420.
18. Kalluri R and Zeisberg M (2006). Fibroblasts in cancer. Nat Rev Cancer 6, 392-401.
19. De Wever O and Mareel M (2002). Role of myofibroblasts at the invasion front. Biol Chem 383, 55-67.
20. Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Dang TD, and Rowley DR (2002). Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res 8, 2912-2923.
21. Zidar N, Gale N, Kambic V, and Fischinger J (2002). Proliferation of myofibroblasts in the stroma of epithelial hyperplastic lesions and squamous carcinoma of the larynx. Oncology 62, 381-385.
22. van Hoorde L, van Aken E, and Mareel M (2000). Collagen type I: a substrate and a signal for invasion. Prog Mol Subcell Biol 25, 105-134.
23. Nakatani K, Okuyama H, Shimahara Y, Saeki S, Kim DH, Nakajima Y, Seki S, Kawada N, and Yoshizato K (2004). Cytoglobin/STAP its unique localization in splanchnic fibroblast-like cells and function in organ fibrogenesis. Lab Invest 84, 91-101.
24. Fordel E, Thijs L, Martinet W Schrijvers D, Moens L, and Dewilde S (2007). Anoxia or oxygen and glucose deprivation in SH-SY5Y cells: a step closer to the unraveling of neuroglobin and cytoglobin functions. Gene 398, 114-122.
25. Xu R, Harrison PM, Chen M, Li L, Tsui TY, Fung PC, Cheung PT, Wang G, Li H, Diao Y, et al. (2006). Cytoglobin overexpression protects against damageinduced fibrosis. Mol Ther 13, 1093-1100.
26. Bruck R, Genina O, Aeed H, Alexiev R, Nagler A, and Pines M (2001). Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats. Hepatology 3, 379-386.
27. Gnainsky Y Kushnirsky Z, Bilu G, Hagai Y, Genina O, Volpin H, Bruck R, Spira G, Nagler A, Kawada N, et al. (2007). Gene expression during chemically induced liver fibrosis: effect of halofuginone on TGF-beta signaling. Cell Tissue Res 328, 153-166.
28. Sheffer Y, Leon O, Pinthus JH, Nagler A, Mor Y, Genin O, Iluz M, Kawada N, Yoshizato K, and Pines M (2007). Inhibition of fibroblast to myofibroblast transition by halofuginone contributes to the chemotherapy-mediated antitumoral effect. Mol Cancer Ther 6, 570-577.
29. Ishiguro M, Iwasaki H, Ohjimi Y, and Kaneko Y (2004). Establishment and characterization of a renal cell carcinoma cell line (FU-UR-1) with reciprocal ASPL-TFE3 fusion transcript. Oncology Rep 11, 1169-1175.
30. Tsuda M, Davis IJ, Argani P, Shukla N, McGill GG, Nagai M, Saito T, Lae M, Fisher DE, and Ladanyi M (2007). TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res 67, 919-929.
31. Zarrin-Khameh N and Kaye KS (2007). Alveolar soft part sarcoma. Arch Pathol Lab Med 131, 488-491.
32. Yang Y, Zhe X, Phan SH, Ullenbruch M, and Schuger L (2003). Involvement of serum response factor isoforms in myofibroblast differentiation during bleomycin-induced lung injury. Am J Respir Cell Mol Biol 29, 583-590.
33. McGaha TL, Phelps RG, Spiera H, and Bona C (2002). Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts. J Invest Dermatol 118, 461-470.
34. Yee KO, Connolly CM, Pines M, and Lawler J (2006). Halofuginone inhibits tumor growth in the polyoma middle T antigen mouse via a thrombospondin-1 independent mechanism. Cancer Biol Ther 5, 218-224.
35. Surowiak P, Murawa D, Materna V, Maciejczyk A, Pudelko M, Ciesla S, Breborowicz J, Murawa P, Zabel M, Dietel M, et al. (2007). Occurrence of stromal myofibroblasts in the invasive ductal breast cancer tissue is an unfavourable prognostic factor. Anticancer Res 27, 2917-2924.
36. Lhonore A, Lamb NJ, Vandromme M, Turowski P, Carnac G, and Fernandez A (2003). MyoD distal regulatory region contains an SRF binding CArG element required for MyoD expression in skeletal myoblasts and during muscle regeneration. Mol Biol Cell 14, 2151-2162.
37. Posern G and Treisman R (2006). Actin' together: serum response factor, its cofactors and the link to signal transduction. Trends Cell Biol 16, 588-596.
38. Matsui H, Kubochi K, Okazaki I, Yoshino K, Ishibiki K, and Kitajima M (1999). Collagen biosynthesis in gastric cancer: immunohistochemical analysis of prolyl 4-hydroxylase. J Surg Oncol 70, 239-246.
39. Nissi R, Bohling T, and Autio-Harmainen H (2004). Immunofluorescence localization of prolyl 4-hydroxylase isoenzymes and type I and II collagens in bone tumours: type I enzyme predominates in osteosarcomas and chondrosarcomas, whereas type II enzyme predominates in their benign counterparts. Acta Histochem 106, 111-121.
40. Fahling M, Perlewitz A, Doller A, and Thiele BJ (2004). Regulation of collagen prolyl 4-hydroxylase and matrix metalloproteinases in fibrosarcoma cells by hypoxia. Comp Biochem Physiol C Toxicol Pharmacol 139, 119-126.
41. Tateaki Y, Ogawa T, Kawada N, Kohashi T, Arihiro K, Tateno C, Obara M, and Yoshizato K (2004). Typing of hepatic nonparenchymal cells using fibulin-2 and cytoglobin/STAP as liver fibrogenesis-related markers. Histochem Cell Biol 122, 41-49.
42. Rosai J, Dias P, Parham DM, Shapiro DN, and Houghton P (1991). MyoDl protein expression in alveolar soft part sarcoma as confirmatory evidence of its skeletal muscle nature. Am J Surg Pathol 15, 974-981.
43. Tallini G, Parham DM, Dias P, Cordon-Cardo C, Houghton PJ, and Rosai J (1994). Myogenic regulatory protein expression in adult soft tissue sarcomas. A sensitive and specific marker of skeletal muscle differentiation. Am J Pathol 144, 693-701.
44. Wang NP, Bacchi CE, Jiang JJ, McNutt MA, and Gown AM (1996). Does alveolar soft-part sarcoma exhibit skeletal muscle differentiation? An immunocytochemical and biochemical study of myogenic regulatory protein expression. Mod Pathol 9, 496-506.
45. Gomez JA, Amin MB, Ro JY, Linden MD, Lee MW, and Zarbo RJ (1999). Immunohistochemical profile of myogenin and MyoD1 does not support skeletal muscle lineage in alveolar soft part sarcoma. Arch Pathol Lab Med 123, 503-507.
46. Cessna MH, Zhou H, Perkins SL, Tripp SR, Layfield L, Daines C, and Coffin CM (2001). Are myogenin and MyoD1 expression specific for rhabdomyosarcoma? A study of 150 cases, with emphasis on spindle cell mimics. Am J Surg Pathol 25, 1150-1157.
47. Walker GA, Guerrero IA, and Leinwand LA (2001). Myofibroblasts: molecular crossdressers. Curr Top Dev Biol 51, 91-107.
48. de Jonge MJ, Dumez H, Verweij J, Yarkoni S, Snyder D, Lacombe D, Marreaud S, Yamaguchi T, Punt CJ, and van Oosterom A (2006). Phase I and pharma-cokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumours. Eur J Cancer 42, 1768-1774.
49. Pines M (2008). Targeting TGFβ signaling to inhibit fibroblast activation as a therapy for fibrosis and cancer: effect of halofuginone. Exp Opin Drug Dis 3, 11-20.
50. Psichari E, Balmain A, Plows D, Zoumpourlis V, and Pintzas A (2002). High activity of serum response factor in the mesenchymal transition of epithelial tumor cells is regulated by RhoA signaling. J Biol Chem 277, 29490-29495.
51. Park MY, Kim KR, Park HS, Park BH, Choi HN, Jang KY, Chung MJ, Rang MJ, Lee DG, and Moon WS (2007). Expression of the serum response factor in hepatocellular carcinoma: implications for epithelial-mesenchymal transition. Int J Oncol 31, 1309-1315.
52. Hua X, Miller ZA, Benchabane H, Wrana JL, and Lodish HF (2000). Synergism between transcription factors TEE3 and Smad3 in transforming growth factor-beta-induced transcription of the Smad7 gene. J Biol Chem 275, 33205-33208.